IP Library › Granted Patent US 12,508,244

Granted Patent B2

US 12,508,244 · App. 18/089,752 · Granted Dec 30, 2025

Therapeutic agent for non-motor symptoms associated with Parkinson's disease

Inventors: Taro Kato (Osaka, JP); Satoko Shimizu (Osaka, JP)

Assignee: NEUROINNOVATECH APS

A61K31/415 A61K45/06 A61P25/08 A61P25/22 A61P25/24

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12,508,244
App. No.: 18/089,752
Granted: Dec 30, 2025
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The purpose of the present invention is to provide: a therapeutic agent or a recurrence preventive agent for serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease; and a method for treating the aforesaid symptoms or preventing the recurrence of the same. A compound represented by formula (1) [wherein each symbol is as defined in the description] or a pharmaceutically acceptable salt thereof can exhibit an effect of treating serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease and/or an effect of preventing the recurrence of the same.

Claims (106)

1 . A method for treating a psychopathic symptom, an agitation symptom, or sleep disorder, associated with a disease presenting with cognitive dysfunction, wherein the disease is at least one selected from the group consisting of Lewy body disease, frontotemporal degeneration, and traumatic brain injury, or preventing a relapse thereof,

the method comprising administering a therapeutically effective amount of a compound of Formula (1),

wherein:

R 1 and R 2 are each independently hydrogen atom, a C 1-6 alkyl group optionally substituted with 1 to 3 deuterium atoms, or a C 3-8 cycloalkyl group,

R 3 and R 4 are each independently hydrogen atom, deuterium atom, or a C 1-6 alkyl group,

R 5 is an optionally-substituted C 4-7 alkyl group or —(CR 8 R 9 ) r -E,

R 6 and R 7 are each independently hydrogen atom, deuterium atom, fluorine atom, or an optionally-substituted C 1-6 alkyl group,

R 8 and R 9 are each independently hydrogen atom, fluorine atom, or an optionally-substituted C 1-6 alkyl group,

A is an optionally-substituted C 6-10 aryl group or an optionally-substituted 5- to 10-membered heteroaryl group,

r is 1, 2, 3, or 4,

E is an optionally-substituted C 3-8 cycloalkyl group, an optionally-substituted C 4-8 cycloalkenyl group, an optionally-substituted 5- to 10-membered saturated heterocyclic group wherein the saturated heterocyclic group comprises 1 to 3 heteroatoms independently selected from the group consisting of oxygen atom and sulfur atom as a constituent atom of the ring, an optionally-substituted C 6-10 aryl group, or an optionally-substituted 5- to 10-membered heteroaryl group,

L is oxygen atom, sulfur atom, or —NR 10 —,

n is 1, 2, or 3,

R 10 is hydrogen atom, a C 1-6 alkyl group, or a C 3-8 cycloalkyl group,

X is hydrogen atom, a C 1-6 alkyl group optionally substituted with fluorine atom, or a halogen atom,

a substituent on the optionally-substituted C 6-10 aryl group and optionally-substituted 5- to 10-membered heteroaryl group is 1 to 2 substituents each independently selected from the group consisting of a halogen atom; a C 1-6 alkyl group optionally substituted with fluorine atom; a C 1-6 alkyloxy group optionally substituted with fluorine atom; hydroxy group; a C 1-6 alkylthio group; a C 6-10 aryloxy group; a C 6-10 arylthio group; cyano group; —CO 2 R 11 ; —SO 2 R 11 ; —NR 10 SO 2 R 11 ; —OSO 2 R 11 ; —COR 12 ; —SO 2 NR 12 R 13 ; —CONR 12 R 13 ; —NR 12 R 13 ; —NR 10 CONR 12 R 13 ; —NR 10 COR 12 ; —CR 12 ═N(OR 11 ); oxime group; a C 3-8 cycloalkyl group; a C 6-10 aryl group; and a 5- to 10-membered heteroaryl group, wherein R 10 is as defined above, R 11 is a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a C 6-10 aryl group, or a 5- to 10-membered heteroaryl group, R 12 and R 13 are each independently hydrogen atom, a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a C 6-10 aryl group, or a 5- to 10-membered heteroaryl group, and the C 6-10 aryl group and 5- to 10-membered heteroaryl group in R 11 , R 12 , and R 13 may be optionally further substituted with a halogen atom, a C 1-6 alkyl group, hydroxy group, or a C 1-6 alkyloxy group,

a substituent on the optionally-substituted C 1-6 alkyl group and optionally-substituted C 4-7 alkyl group is 1 to 2 substituents each independently selected from the group consisting of fluorine atom; hydroxy group; and a C 1-6 alkyloxy group optionally substituted with fluorine atom, and

a substituent on the optionally-substituted C 3-8 cycloalkyl group, optionally-substituted C 4-8 cycloalkenyl group, and optionally-substituted 5- to 10-membered saturated heterocyclic group is 1 to 2 substituents each independently selected from the group consisting of fluorine atom; a C 1-6 alkyl group optionally substituted with fluorine atom; hydroxy group; and a C 1-6 alkyloxy group optionally substituted with fluorine atom,

or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

2 . The method according to claim 1 , wherein R 1 and R 2 are each independently hydrogen atom, methyl group, or methyl group substituted with 1 to 3 deuterium atoms, R 3 is hydrogen atom, deuterium atom, or methyl group, and R 4 is hydrogen atom or deuterium atom.

3 . The method according to claim 1 , wherein A is an optionally-substituted C 6-10 aryl group.

4 . The method according to claim 1 , wherein X is hydrogen atom.

5 . The method according to claim 1 , wherein L is oxygen atom.

6 . The method according to claim 1 , wherein n is 1.

7 . The method according to claim 1 , wherein R 1 , R 3 , and R 4 are hydrogen atom and R 2 is methyl group.

8 . The method according to claim 1 , wherein R 6 and R 7 are each independently hydrogen atom or deuterium atom and R 8 and R 9 are hydrogen atom.

9 . The method according to claim 1 , wherein E is an optionally-substituted C 3-8 cycloalkyl group, an optionally-substituted 5- to 10-membered saturated heterocyclic group wherein the saturated heterocyclic group comprises 1 to 3 oxygen atoms as a constituent atom of the ring, or an optionally-substituted phenyl group.

10 . The method according to claim 1 , wherein E is an optionally-substituted C 3-8 cycloalkyl group.

11 . The method according to claim 1 , wherein r is 1 or 2.

12 . The method according to claim 1 , wherein R 5 is an optionally-substituted C 4-7 alkyl group.

13 . The method according to claim 1 , wherein the compound of Formula (1) is at least one selected from the group consisting of:

1-[5-(benzyloxy)-1-(cyclohexylmethyl)-1H-pyrazol-3-yl]-N-methylmethanamine;

1-{1-(cyclohexylmethyl)-5-[(2-fluorobenzyl)oxy]-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{5-[(2-chloro-4-fluorobenzyl)oxy]-1-(cyclohexylmethyl)-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{1-(cyclohexylmethyl)-5-[(4-fluoro-2-methylbenzyl)oxy]-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{1-(cyclohexylmethyl)-5-[(2,5-difluorobenzyl)oxy]-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{5-[(5-chloro-2-fluorobenzyl)oxy]-1-(cyclohexylmethyl)-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{5-[(2-chloro-5-fluorobenzyl)oxy]-1-(cyclohexylmethyl)-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{1-(cyclohexylmethyl)-5-[(2,5-dichlorobenzyl)oxy]-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{1-(cyclopentylmethyl)-5-[(4-fluorobenzyl)oxy]-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{5-[(2-chlorobenzyl)oxy]-1-(cyclopentylmethyl)-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{1-(cyclopentylmethyl)-5-[(2,4-difluorobenzyl)oxy]-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{1-(cyclopentylmethyl)-5-[(2,5-difluorobenzyl)oxy]-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{5-[(5-chloro-2-fluorobenzyl)oxy]-1-(cyclopentylmethyl)-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{5-[(2,5-difluorobenzyl)oxy]-1-(3,3-dimethylbutyl)-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{5-[(2,5-difluorobenzyl)oxy]-1-(3-methylbutyl)-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{5-[(5-chloro-2-fluorobenzyl)oxy]-1-(3-methoxy-3-methylbutyl)-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{1-(cyclopentylmethyl)-5-[(2,4,5-trifluorobenzyl)oxy]-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{1-(2-cyclopentylethyl)-5-[(2,5-difluorobenzyl)oxy]-1H-pyrazol-3-yl}-N-methylethanamine;

N-methyl-1-{1-(3-methylbutyl)-5-[(2,4,5-trifluorobenzyl)oxy]-1H-pyrazol-3-yl}methanamine;

1-{1-(3,3-dimethylbutyl)-5-[(2,4,5-trifluorobenzyl)oxy]-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{1-(4-fluorobenzyl)-5-[(2-fluorobenzyl)oxy]-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{5-[(2,5-difluorobenzyl)oxy]-1-(4-fluorobenzyl)-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{5-[(2,5-difluorobenzyl)oxy]-1-(4-methylbenzyl)-1H-pyrazol-3-yl}-N-methylmethanamine;

N-methyl-1-{1-(4-methylbenzyl)-5-[(2,4,5-trifluorobenzyl)oxy]-1H-pyrazol-3-yl}methanamine;

1-{5-[(5-chloro-2-fluorobenzyl)oxy]-1-(cyclopropylmethyl)-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{5-[(5-chloro-2-fluorobenzyl)oxy]-1-(2-methylpropyl)-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{5-[(2,5-difluorobenzyl)oxy]-1-(2,2-dimethylpropyl)-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{5-[(5-chloro-2-fluorobenzyl)oxy]-1-(2,2-dimethylpropyl)-1H-pyrazol-3-yl}-N-methylmethanamine;

1-[1-benzyl-5-(benzyloxy)-1H-pyrazol-3-yl]-N-methylmethanamine;

1-{5-[(4-fluoro-2-methylbenzyl)oxy]-1-(tetrahydro-2H-pyran-2-ylmethyl)-1H-pyrazolo-3-yl}-N-methylmethanamine;

1-[5-(benzyloxy)-1-(bicyclo[2.2.1]hept-2-ylmethyl)-1H-pyrazol-3-yl]-N-methylmethanamine;

1-{1-(bicyclo[2.2.1]hept-2-ylmethyl)-5-[(2,5-difluorobenzyl)oxy]-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{1-(bicyclo[2.2.1]hept-2-ylmethyl)-5-[(5-chloro-2-fluorobenzyl)oxy]-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{5-[(3-chlorobenzyl)oxy]-1-(2-oxabicyclo[2.2.2]oct-3-ylmethyl)-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{5-[(2,5-difluorobenzyl)oxy]-1-[(4,4-difluorocyclohexyl)methyl]-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{5-[(2,5-difluorobenzyl)oxy]-1-[(1-fluorocyclohexyl)methyl]-1H-pyrazol-3-yl}-N-methylmethanamine;

2-[({1-(cyclopentylmethyl)-3-[(methylamino)methyl]-1H-pyrazol-5-yl}oxy)methyl]benzonitrile;

1-{1-(4-chlorobenzyl)-5-[(2,5-difluorobenzyl)oxy]-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{5-[(5-chloro-2-fluorobenzyl)oxy]-1-(2-ethylbutyl)-1H-pyrazol-3-yl}-N-methylmethanamine;

1-[5-(benzyloxy)-1-(1-cyclopentylethyl)-1H-pyrazol-3-yl]-N-methylmethanamine;

1-{5-[(5-chloro-2-fluorobenzyl)oxy]-1-(1-cyclopentylethyl)-1H-pyrazol-3-yl}-N-methylmethanamine;

1-[5-(benzyloxy)-1-(1-cyclohexylethyl)-1H-pyrazol-3-yl]-N-methylmethanamine;

1-{1-(1-cyclohexylethyl)-5-[(2-fluorobenzyl)oxy]-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{1-(1-cyclohexylethyl)-5-[(4-fluorobenzyl)oxy]-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{5-[(2-chlorobenzyl)oxy]-1-(1-cyclohexylethyl)-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{1-(1-cyclohexylethyl)-5-[(2-methylbenzyl)oxy]-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{1-(1-cyclohexylethyl)-5-[(3-methylbenzyl)oxy]-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{1-(1-cyclohexylethyl)-5-[(2,4-difluorobenzyl)oxy]-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{5-[(2-chloro-4-fluorobenzyl)oxy]-1-(1-cyclohexylethyl)-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{1-(1-cyclohexylethyl)-5-[(4-fluoro-2-methylbenzyl)oxy]-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{1-(1-cyclohexylethyl)-5-[(2,5-difluorobenzyl)oxy]-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{5-[(5-chloro-2-fluorobenzyl)oxy]-1-(1-cyclohexylethyl)-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{1-(1-cyclohexylethyl)-5-[(2-fluoro-5-methylbenzyl)oxy]-1H-pyrazol-3-yl}-N-methylmethanamine;

1-[5-(benzyloxy)-1-(1-cyclohexyl-2-fluoroethyl)-1H-pyrazol-3-yl]-N-methylmethanamine;

1-{5-(benzyloxy)-1-[(1-methylcyclohexyl)methyl]-1H-pyrazol-3-yl}-N-methylmethanamine;

1-{5-[(3-chlorobenzyl)oxy]-1-(3,4-dihydro-2H-chromen-2-ylmethyl)-1H-pyrazol-3-yl}-N-methylmethanamine;

N-({1-(cyclohexylmethyl)-5-[(2,5-difluorobenzyl)oxy]-1H-pyrazol-3-yl}methyl)cyclopropanamine;

N-({1-(cyclohexylmethyl)-5-[(2,5-difluorobenzyl)oxy]-1H-pyrazol-3-yl}methyl)ethanamine;

1-{1-(cyclohexylmethyl)-5-[(2,5-difluorobenzyl)oxy]-1H-pyrazol-3-yl}methanamine;

1-{1-(cyclohexylmethyl)-5-[difluoro(phenyl)methoxy]-1H-pyrazol-3-yl}-N-methylmethanamine;

1-[5-(benzyloxy)-1-(cyclohexylmethyl)-1H-pyrazol-3-yl]-N-methyl( 2 H 2 )methanamine;

1-[5-(benzyloxy)-1-(cyclohexylmethyl)-1H-pyrazol-3-yl]-N-( 2 H 3 )methyl( 2 H 2 )methanamine;

1-[5-(benzyloxy)-1-(cyclohexylmethyl)-1H-pyrazol-3-yl]-N-( 2 H 3 )methylmethanamine;

1-[1-(cyclopentylmethyl)-5-{[(2,5-difluorophenyl)( 2 H 2 )methyl]oxy}-1H-pyrazol-3-yl]-N-methylmethanamine;

1-[5-{[(5-chloro-2-fluorophenyl)(2H 2 )methyl]oxy}-1-(cyclopentylmethyl)-1H-pyrazol-3-yl]-N-methylmethanamine;

1-[1-(cyclohexylmethyl)-5-{[(2,5-difluorophenyl)( 2 H 2 )methyl]oxy}-1H-pyrazol-3-yl]-N-methylmethanamine;

1-[5-{[(5-chloro-2-fluorophenyl)( 2 H 2 )methyl]oxy}-1-(cyclohexylmethyl)-1H-pyrazol-3-yl]-N-methylmethanamine; and

1-[5-{[(2,5-difluorophenyl)( 2 H 2 )methyl]oxy}-1-(3,3-dimethylbutyl)-1H-pyrazol-3-yl]-N-methyl( 2 H 2 )methanamine,

or a pharmaceutically acceptable salt thereof.

14 . The method according to claim 1 , wherein the compound has the action of antagonizing a serotonin 5-HT2A receptor, inhibiting a serotonin transporter, and antagonizing a serotonin 5-HT2C receptor.

15 . The method according to claim 1 , wherein the compound of Formula (1) is 1-{1-(cyclopentylmethyl)-5-[(2,5-difluorobenzyl)oxy]-1H-pyrazol-3-yl}-N-methylmethanamine or pharmaceutically acceptable salts thereof.

16 . The method according to claim 1 , wherein the compound of Formula (1) is 1-{5-[(2,5-difluorobenzyl)oxy]-1-(3,3-dimethylbutyl)-1H-pyrazol-3-yl}-N-methylmethanamine or pharmaceutically acceptable salts thereof.

17 . The method according to claim 1 , wherein the compound of Formula (1) is N-methyl-1-{1-(3-methylbutyl)-5-[(2,4,5-trifluorobenzyl)oxy]-1H-pyrazol-3-yl}methanamine or pharmaceutically acceptable salts thereof.

18 . The method according to claim 1 , wherein the compound of Formula (1) is 1-{5-[(5-chloro-2-fluorobenzyl)oxy]-1-(cyclopropylmethyl)-1H-pyrazol-3-yl}-N-methylmethanamine or pharmaceutically acceptable salts thereof.

19 . The method according to claim 1 , wherein the compound of Formula (1) is 1-{5-[(5-chloro-2-fluorobenzyl)oxy]-1-(2-methylpropyl)-1H-pyrazol-3-yl}-N-methylmethanamine or pharmaceutically acceptable salts thereof.

Assignments (1)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2025

From: SUMITOMO PHARMA CO., LTD.

To: NEUROINNOVATECH APS

Reel/Frame 072810/0091 →

Priority Claims (1)

JP 2017-004498 · Jan 13, 2017 · national

Continuity (2)

Division 16476925

Related Publication 20230149357A1 · May 18, 2023

References Cited (41)

US 8569353B2 · Sasaki · 2013 [cited by examiner]

US 9663472B2 · Sasaki · 2017 [cited by examiner]

US 10183913B2 · Sasaki · 2019 [cited by examiner]

US 20050222206A1 · Cohen et al. · 2005 [cited by applicant]

US 20050261278A1 · Weiner et al. · 2005 [cited by applicant]

US 20060003996A1 · Roth et al. · 2006 [cited by applicant]

US 20060063757A1 · Forbes et al. · 2006 [cited by applicant]

US 20100004264A1 · Xiong et al. · 2010 [cited by applicant]

US 20130116296A1 · Sasaki et al. · 2013 [cited by applicant]

EP 2594559 · 2013 [cited by applicant]

JP 2006504794 · 2006 [cited by applicant]

JP 2008546691 · 2008 [cited by applicant]

JP 2010505832 · 2010 [cited by applicant]

TW 263497 · 1992 [cited by applicant]

WO 2012008528 · 2012 [cited by applicant]

WO 2013157511 · 2013 [cited by applicant]

International Search Report issued Apr. 10, 2018 in International (PCT) Application No. PCT/JP2018/000568. [cited by applicant]

Written Opinion of International Searching Authority issued Apr. 10, 2018 in International (PCT) Application No. PCT/JP2018/000568. [cited by applicant]

Rabey, “Hallucinations and psychosis in Parkinson's disease”, Parkisonism and Related Disorders, vol. 155, pp. S105-S110, 2009. [cited by applicant]

Breier et al., “Olanzapine in the Treatment of Dopamimetic-Induced Psychosis in Patients with Parkinson's Disease”, Biological Psychiatry, vol. 52, No. 5, pp. 438-445, 2002. [cited by applicant]

Ondo et al., “Olanzapine Treatment for Dopaminergic-Induced Hallucinations”, Movement Disorders, vol. 17, No. 5, pp. 1031-1035, 2002. [cited by applicant]

Gòmez-Esteban et al., “Use of Ziprasidone in Parkinsonian Patients With Psychosis”, Clinical Neuropharmacology, vol. 28, No. 3, pp. 111-114, 2005. [cited by applicant]

Pollak et al., “Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up”, Journal of Neurology Neurosurgery Psychiatry, vol. 75, No. 5, pp. 689-695, 2004. [cited by applicant]

Cummings et al., “Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial”, The Lancet, vol. 383, pp. 533-540, 2014. [cited by applicant]

Vanover et al., “Pharmacological and Behavioral Profile of N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-y1)-N′-(4-(2-methylpropyloxy)phenylmethyl) Carbamide (2R,3R)-Dihydroxybutanedioate (2:1) (ACP-103), a Novel 5- H… [cited by applicant]

Martinez-Martin et al., “Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale”, European Journal of Neurology, vol. 22, pp. 37-43, 2015. [cited by applicant]

Duncan et al., “Health-Related Quality of Life in Early Parkinson's Disease: The Impact of Nonmotor Symptoms”, Movement Disorder, vol. 29, No. 2, pp. 195-202, 2014. [cited by applicant]

Garcia-Borreguero et al., “Parkinson's disease and sleep”, Sleep Medicine Reviews, vol. 7, No. 2, pp. 115-129, 2003. [cited by applicant]

Emre, “Dementia associated with Parkinson's disease”, The Lancet Neurology, vol. 2, pp. 229-237, 2003. [cited by applicant]

Oberndorfer et al., “Effects of Selective Serotonin Reuptake Inhibitors on Objective and Subjective Sleep Quality”, Neuropsychobiology, vol. 42, pp. 69-81, 2000. [cited by applicant]

Landolt et al., “Antagonism of serotonergic 5-HT [cited by applicant]

Avlar et al., “Improving Temporal Cognition by Enhancing Motivation”, Behavoral Neuroscience, vol. 129, No. 5, pp. 576-588, 2015. [cited by applicant]

Marek et al., “Synergistic Action of 5-HT [cited by applicant]

Rénéric et al., “In the rat forced swimming test, chronic but not subacute administration of dual 5-HT/NA antidepressant treatments may produce greater effects than selective drugs”, Behavioural Brain Research, vol. 136… [cited by applicant]

Andersen et al., “Anti-depressive treatment in Parkinson's disease: A Controlled Trial of the Effect of Nortriptyline in Patients With Parkinson's Disease Treated With L-DOPA”, Acta Neurologica Scandinavica, vol. 62, No… [cited by applicant]

Vijayapandi et al., “Biphasic Effects of Losartan Potassium on Immobility in Mice”, Yakugaku Zasshi, vol. 125 No. 8, pp. 653-657, 2005. [cited by applicant]

Hanagasi et al., “Treatment of behavioural symptoms and dementia in Parkinson's disease”, Fundamental & Clinical Pharmacology, vol. 19, pp. 133-146, 2005. [cited by applicant]

Clinical Practice Guideline for Parkinson's disease 2011 edited by Japanese Society of Neurology. [cited by applicant]

Caine, “I-Dopa in the treatment of parkinsonism”, Clinical Pharmacology & Therapeutics, vol. 11, No. 6, pp. 789-801 (1970). [cited by applicant]

Extended Search Report issued Aug. 27, 2020 in corresponding European Patent Application No. 18739127.1. [cited by applicant]

Cussac, D. et al., “Antagonist properties of the novel antipsychotic, S16924, at cloned, human serotonin 5-HT2c receptors: a parallel phosphatidylinositol and calcium accumulation comparison with clozapine and haloperid… [cited by applicant]